Respiratory Medicine Case Reports (Jan 2024)

A case of autoimmune pulmonary alveolar proteinosis responding to oral statin therapy

  • So Shimamura,
  • Honami Morikawa,
  • Ken Shinohara,
  • Hiroki Ohkoshi,
  • Chisa Omori,
  • Yuuki Hoshino,
  • Yoshinori Uchida,
  • Saiki Masafumi,
  • Shinnosuke Ikemura,
  • Naoki Ohishi,
  • Tetsuo Kondo,
  • Kenzo Soejima

Journal volume & issue
Vol. 50
p. 102042

Abstract

Read online

There is no approved drug treatment for autoimmune pulmonary alveolar proteinosis (APAP), although traditionally requires complex treatments such as whole lung lavage (WLL). We herein report on a 67-year-old man diagnosed with APAP. Treatment with atorvastatin (5 mg daily) resulted in significant improvement in symptoms, lung function, and computed tomography findings, with enhanced oxygenation, although serum anti-GM-CSF antibody levels remained elevated. This case suggests that the remission observed in this case could potentially be attributed to a direct effect of atorvastatin within the pulmonary alveoli. Statins may be considered as one of the treatment options for APAP.